Vazegepant HCl ( —— )

Catalog No. M22411 CAS No. 1414976-20-7

Vazegepant is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	215	Get Quote
10MG	317	Get Quote
25MG	536	Get Quote
50MG	763	Get Quote
100MG	1053	Get Quote
200MG	Get Quote	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Group Booking Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Vazegepant HCl
Note

Research use only, not for human use.
Brief Description

Vazegepant is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study.
Description

Vazegepant is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study.
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Others
Research Area

——
Indication

——

Chemical Information

CAS Number

1414976-20-7
Formula Weight

675.3
Molecular Formula

C36H47ClN8O3
Purity

>98% (HPLC)
Solubility

——
SMILES

Cl.CN1CCC(CC1)N1CCN(CC1)C(=O)[C@@H](Cc1cc(C)c2[nH]ncc2c1)NC(=O)N1CCC(CC1)c1cc2ccccc2[nH]c1=O
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1.Moreno-Ajona D , Abigail Pérez-Rodríguez, Goadsby P J . Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment[J]. Current Opinion in Neurology, 2020, 33(3):1.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

Product			Quantity Required*
Name *			E-mail Address *
Organization *			Phone Number
Remarks